newsfilter
← Latest News
Earnings Call Transcripts·

ALX ONCOLOGY HOLDINGS INC. - ALX ONCOLOGY HOLDINGS INC

My name is Roger Song, Senior Analyst at CoverSmithKaib Biotech in the US. It is my pleasure to have a five-star chat with ALX Oncology and then we have our CEO Jason Lemon and then CMO Barbara. Welcome. Jason, why don't you give us a mini overview of ALX. You have a two major program. You will have a lot of the updates in the coming months and then give us some updates yeah sure so again thanks for having us appreciate the invite it's been a good meeting for us um you know so we're at alex we're developing two novel therapies that we think can be potentially first and best in class the first program is a borbicept which is an anti-cd47 this is the program we've been working on since the company's inception we've now dosed over 800 patients i'm really excited about the trajectory of the program. I think as some of you may know, CD47 has certainly been a challenged target in terms of drug development. But, you know, that's not due to the target itself. It's an incredibly important pathway, an important invasion mechanism for tumors. And we think given our approach of bifurcating the eat me signal from the don't eat me single has really allowed us to target CD47 in a way that's been much more safe and effective. And I think that combined with a new understanding around the role of CD47 as a biomarker has really led to an important inflection point with our program in that this is very much now a targeted IO play. Through this work, through the 800 patients plus that we've treated, we know where the drug works best, and that's how we're designing. and we can talk about the current study and REST that we're running and excited about. And then our second program is AOX 2004. This is an in-house developed EGFR targeted ADC that we have been working on since 2021. The effort here was to really develop an ADC with a singular ability to target EGF-R. And what we saw at the time and we still see is a real opportunity for monospecific EGFR ADC that could be safer and less toxic than some of the programs in the past that have failed, but also incredibly potent. And that's what we think we have. and we're very much looking forward to sharing data from that program next month and just updated our guidance at earnings on Monday to specify that we'll have a KOL event coming up in December to run through that data, which we're looking forward of sharing. Excellent. All right. I think we can flip the order because you will have the ALX 2004 data update very soon. Yep, everybody wants to talk about what's first. All right, here we go. Yes, let's do it. So how much you can say right now the dosing and enrollment? Because I remember last time you already go up to 5 to 5.5. And then how should we think about the data sets we're going to look like and the dosage level? Yeah, so we started treating patients last August, so a little over a year now. I think in the past we've communicated that we've been able to move through dose escalation relatively rapidly. At least those started at 1 mg per kick, doubled to 2, doubled to 4, and have continued to increase beyond that. And I think with this update, we also refined guidance on that earlier this week that we'll have, you know, call it 35 to 40 patients to report on, of which 15 or more will be at efficacious doses in the tumor types where we're focused, and that's mainly head and neck, lung, and esophageal. So, you know, I think in the past we've been guiding to more of a safety update. We certainly will be commenting on safety in the therapeutic window and what we're seeing there. But also I think with 15-plus patients that are at the right doses in tumor types of interest, we should be able to comment on our activity as well. Getting even more interesting for the data update. Okay, great. So maybe before we talk about efficacy, on the safety side, I believe, you know, EGFR has some, you know, the target-related talks, and then with your ADC, how you think you can address that, and then what's the target profile on the tolerability side? And if you can comment on anything right now you have been seeing, that would be awesome. Yeah, sure. I can talk about the design of the ADC and maybe Barb can talk about sort of what we hope to see. I think on the design front, I think what we recognized very early is that most, if not all, of the constructs, both bispecific and ADCs, have used cetuximab as the epitope. And we identified, through going back through the history of EGFR development, an antibody called metuzumab, which was developed by Merck-Sorano after a very large screening effort to identify an antibody that selectively binds to tumor over skin, for example. And I think that choice of epitope is really important because what we're hoping to see is that translate in the clinic in the form of reduced EGF-R-related toxicity. And I think, you know, that combined with the efforts that we did to optimize the affinity as well as we spent a lot of time on the linker payload construct. And we think we have a, again, as I mentioned, a very potent molecule, but one that we think should have a pretty wide therapeutic window. So do you want to talk about specifics? Yeah. So I would say rash is probably the most important. It's very problematic for patients. Cetuximab, panetumumab, the monoclonal antibodies have a range of rash incidents in the 70, 80, 90% range. And, in fact, that was the reason why previous EGFR antibody drug conjugates were not able to be brought forward. They were limited by rash. And so with the protein engineering that was done, the selection of the antibody epitope of metuzumab, affinity tuning, a number of things that we have done, we really hope to minimize the incidence of rash. And then, so that'll be the, I think, what people are most interested in seeing in terms of our safety profile is have we accomplished that? Got it. You say minimize. How much, you know, do you have any numbers when we see the data will be, oh, okay, that's a great data, number one. Number two, how about the GI and the LUN? Anything else related to the EGFR you want to try to mitigate? Yeah, I would say that in terms of a rate that would be of interest, if the historic control of a cetuximab is 70%, 80%, 90%, you know to see half or less. So 30% or less would be a good number in terms of rash. Seeing low-grade, grade 1 or 2, but not grade 3, would be another good indicator. In terms of other toxicities, we've got a topo-1 molecule. We've got DAR-8. So we've Got a potent delivery of topo 1. And so you will imagine that chemotherapy-type toxicities, myelosuppression, nausea, mucositis, stomatitis, maybe some diarrhea would also be things that we'll be looking closely at in our update. Got it. Do you expect that will be problematic, or that's still within the manageable kind of range in 10-ish percent? Yeah, I think those, for me, as an oncologist, I thing become the more manageable because there are ways to mitigate many of those toxicities. You know, myelosuppression is something that oncologists deal with all the time through neupogen and other supportive care measures, myeloid growth factor support, for example. But we are really looking for a molecule that patients are able to take over a longer period of time, which means mitigating or minimizing, keeping the rates of nausea, vomiting, diarrhea, things like that down would be an important aspect of the target product profile. Got it. Okay, great. And then let's move on to the efficacy. I think, Jason, you mentioned 15 patients at a separated dose. should we think about this is a you know you're pushing the dose a higher multiple higher uh you know dose level or you have a certain level you feel you you like it and expand that so how many dose level we should expect within the 15 window uh and then we can talk about it yeah yeah i mean the goal of of dose escalation is to drive dose up to to hit dlts which is which is what we did and then, you know, backfill and drop into a range that you think is going to be the right window. So that's what we'll be prepared to report on. I think a couple really important points about this study. One is it's a U.S.-only study. So these are all large academic centers, think Moffitt, MD Anderson, and the like, where patients are truly receiving the best in standard of care. And this is a very late-line population. So on average, these patients entering our study are a fourth-line population, so a very advanced head and neck population and a very advance lung population, for example. And the benchmarks there are really pretty woeful. I mean, it's another line of chemo, perhaps a clinical trial, so I think 5% to maybe high single-digit percent ORR is what you'd expect. You know, I think for us, and we've seen competitive data come in at 10 to call it 20%, I think if we're able to deliver north 20%, that would be outstanding. And, you know, as I think one analyst pointed out this week, if we can deliver 30% or better, that'd be transformational. Because, again, I Think that starts to approach the second line benchmarks. and if we're able to do that in a fourth line setting I think it really bodes well because and we can talk about where we're going but in terms of what's next is to move up line so from fourth line into second line across both of those indications is where we and yeah again I think if we can show some real potency in this data set will be set up well to I think drive even more gains on ORR going forward. Got it. Great. Yeah, I think the benchmark, I agree with you, right? It's a high thermal data maximum for standard care. And then 30%, you know, in those ley lines, solid tumor, no matter which probably the tumor you're targeting, definitely will be very meaningful. Just when we see this 15 patient, we break out by tumor type and then also by dose level and then that will be metrics matrix will be in a smaller and how we gonna say this is a 30 percent or 40 percent or you know how should we i mean our our goal i think is really to be transparent and share what we have um you know i think the facts are friendly in the dose escalation you want to know and we certainly want to share what you have so we're going to break it out in all those ways we'll share swimmers we're gonna share waterfall spider plot etc so i think it'll It'll be a really transparent look at, you know, a very sick patient population. And, again, this molecule was designed to drive real potency. And, you now, the hope here is that's what comes through in the data. Got it. And then you have three tumor types you want to focus. Is this enrollment really balanced? Or when we see the data, will one or two tumors have more patients and it will be more mature for you to make a decision. Yeah, I mean, I think one of the things that, you know, Barb and the team did a nice job of is a lot of times in these studies you're enrolling a basket of five or ten different tumor types, which makes it very challenging from a signal-finding perspective. And so we very consciously, once we hit four micks per gig, aimed our enrollment towards head and neck and lung because that's where we see the best commercial opportunity. And so, in fact, when we share our data, that's what you'll see is most of those 15-plus patients will be head and neck and lung patients with a smattering of esophageal or CRC. But, again, I think that's why we'll be so informative about this data set. I mean, there's no question it's still early days, and this data setting will be early. But I think it should be enough, I think, to see signal and, again, to be able to define the therapeutic window that we're looking at. Okay. Got it. And then after that, would you be able – you probably – maybe take a step back. What's the follow-up for those 15 patients going to look like? I mean, if you think about what we've said publicly is we entered four mgs per kg earlier this year. um so you know think about from that point to today um you know it's it's going to be several months um so again this is primarily focused on orr um but as i mentioned we'll be sharing swimmers for example spider plot which i think will give a sense of overall durability and um and that's important i mean with an adc these days there's a lot of debate about what's driving durability and where there's a lack of durability and one of the things i think that it's super clear is you have to keep these patients on drug so we want to be able to show that we've done that and have a relatively low dose reduction or discontinuation rate got it okay and then how about the egfi expression level would you uh also um you know build some coloration with the level or that's you know because they are widely expressed as done as you did um we get barb can certainly add to this but we picked those four tumor types because they're all relatively high and or have been responsive to egfr therapies in the past so within head and neck and and lung both of those are uh are high expressors um and again i think what would be ideal is that we show that expression is really not all that important um and we'll be commenting on that as well so i don't just that we are looking retrospectively we're collecting tissue on everyone and looking to see if there is a relationship with egfr expression but i agree with jason these are tumor types that ubiquitous ubiquitously express egfr and and that may be enough got it okay great um let's see uh you mentioned earlier the competitive landscape for uh for the egfr uh for that for the head neck and small cell line. Anything emerging on the EGFR side? You mentioned your very novel epithelium. That's one way to address the main issue with the EFFR. Any other ones you think it would be interesting to put on the radar? Yeah, I mean, I think certainly in head and neck, right, there's a lot of EGFR activity with the bispecifics. We saw recent data from PDO that I think there's no question that PDO will be frontline standard of care going forward. AMI, you know, recently had an accelerated approval in the second line. So there's a lot of activity on the bisspecific front. Again, what's really key about our molecule is all of those use cetuximab as their EGFR construct, and we use metuzumab and that's important that unique binding is important because for example if a patient sees pedo in the front line there is a very good chance that that binding site will mutate off of cetux and we will then have a ADC that using metuzamab that binds in a different pocket so I think that enables us to go post EGFR and we'll have data in this update of the patients that have seen EGFR, but it also enables us to combine in a way that's very unique. I mean, if you think about comparables in frontline breast, you have an HER2 plus Progetta. So two different HER2 epitopes that have now defined standard of care. And there's an opportunity for us, again, given this unique epitope to combine with PETO or combine with AMI. And I think that is very, very unique There's not other ADCs or bispecifics. For example, those drugs can't be combined with each other. So that's really a key part of our differentiation as well. Excellent. That's a very good point. And then that also linked to your strategy moving to the earlier line, right? So yes, you know, maybe become the first line, and then maybe combine with you, it can be even improve the first nine, the performance. So what is the strategy moving to the earlier line? What kind of data do you need to generate before you can commit more resources into this? Yeah, I mean, I think in head and neck, well, broadly, it's been demonstrated that what can compete with next generation biospecifics? Well, I Think well-designed ADCs can, and that's what we have. And so in head of neck, we have the potential to be the first topo ADC in the class. And I think that is a really unique advantage. So we certainly can start second-line monotherapy, and that's what we intend to do. But as I mentioned, we have combination potential either with the other EGFRs or we would think about a PEMBRO combination, which would bring us to the front line. But again, topo is a very well-tolerated payload, well-characterized, and the other programs that are EDCs in the space are MMAE-based. So that's the real opportunity for us. And then in lung, we're particularly focused on wild-type, where there's still a lot of room for new entry from topos. I think on the mutant side, there's DATO and SAC-TMT and others coming, but on the wild-type side, we see more opportunity, particularly in the squam setting, and that lines up well for our drug because squam lung tumors express EGFR very high. And so that opportunity has been hard for competitors, particularly Dato and some of the others, and that's a real opportunity for us. So I think EGF-R can appear crowded, and certainly there's a lot of activity on the bispecific side, but when you look at what's being done with EGfr monospecific ADCs, we have opportunity in both of those classes to get there first. Okay, got it. And then after this data set, how much more you need before you can talk with the FDA to design a potential pivotal phase two in the monotherapy in the later life? Yeah, I mean, Barb can talk about how we think about regulatory. I think from a strategy perspective, a corporate perspective, we want to have this program be in a place towards the end of really this time next year where we're gearing up for a phase three and a registration study, and I think that's doable with where we are now. Yeah, to be pivotal trial ready, we would take data in and whether, you know, it's often called an end of phase two meeting. It doesn't need to be the end. It just needs to have some data that provides that signal of activity. You can understand the safety, and you have some rationale for the dose that you would like to select. And so having that information in 2027 to allow us to be pivotal trial ready potentially by the end of next year would be great. Awesome. And then the population-wise, you will start with the second line, and then would that require a randomized trial or that's a single-arm trial? I think it just depends. I mean, we, you know, AMI, for example, drove an AA and second line head and neck off of single arm data. So I think it is possible. Again, it's data dependent. Certainly, as we think about moving into the front line, we would need a randomized study. And I think lung is TBD, too. There's definitely a high unmet need in squamous wild type lung. And so I think, again, data dependent, we could think about an AA path there. And we haven't talked much about esophageal, but that's certainly a smaller indication relative to those two, but potentially a faster path to market and that indication as well. So a lot of this is data dependent, but I do think we have the potential to go pretty fast here. Got it. Not surprising we spend most of the time on this data set. You just announced you're going to have data. This is consistent with all of our meetings today, so it's perfect. Okay, great. But also you have the EVO in the ongoing phase two, and then that is not registrational, but also prepare you for the period. So how much update you will have there? And then, you know, we're going to see data next year. What's the expectation? Yeah, so we also in earnings on Monday just shared that we'll have more patients there as well. So we're now guiding to 120 patients second half of the year. And again, I think it'll be a really important update this is in the post and HER2 setting it's very clear even coming off of ESMO that patients who progress on in HER2 are not doing well at all and it is a screaming unmet need with a lot of patients and so we feel really good about the need we're addressing enrollment and the investigator enthusiasm has been better than expected so looking forward to that update back after next year Excellent, alright I think we're almost there and then anything else when you touch maybe a cash position Yeah, we're well funded we raised $150 million in January, brought in some great groups with RA Blackstone, Orbamed etc so I think that set us up well from a balance sheet perspective so we can certainly execute through all the milestones we talked about and looking forward to our big next 12 months. Excellent. Thank you, Jason. Thank you. I really appreciate it. Thank everyone.

Company
ALX ONCOLOGY HOLDINGS INC
Keywords
ALX ONCOLOGY HOLDINGS INC